Investigational approaches for mesothelioma

Frontiers in Oncology

Volumn 1, Issue AUG, 2011, Pages

  Surmont, Veerle F ^a   van Thiel, Eric R E ^b   Vermaelen, Karim ^a   van Meerbeeck, Jan P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

Chemotherapy; Mesothelioma; Targeted therapy

Indexed keywords

EID: 84858257206     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00022     Document Type: Review

References (152)

1. Ahamed, A., Stevens, C. W., Smyth, W. R., Vaporciyan, A. A., Komaki, R., Kelly, J. F., Liao, Z., Starkschall, G., and Forster, K. M. (2003). Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 355, 768-775.
2. Allen, A. L., Czerminska, M., Janne, P. A., Sugarbaker, D. J., Bueno, R., Harris, J. R., Court, L., and Baldini, E. H. (2006). Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 65, 640-645.
3. Anonymous. (n.d. a). Dasatinib in Resectable Malignant Pleural Mesothelioma, NCT00652574. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
4. Anonymous. (n.d. b). Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma, NCT00509041. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
5. Anonymous. (n.d. c). Intrapleural Gene Transfer for Pleural Mesothelioma (IFN-alpha), NCT01212367. Available at: http://www.clinicaltrials.gov [accessed January 2011].
6. Anonymous. (n.d. d). Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients with Malignant Pleural Mesothelioma NCT01064648. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
7. Anonymous. (n.d. e). Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma. NCT00700336. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
8. Anonymous. (n.d. f). Phase II Study Of ET-743 In Patients With Unresectable Malignant Pleural Mesothelioma. NCT00027508. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
9. Anonymous. (n.d. g). Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy, NCT01160458. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
10. Anonymous. (n.d. h). Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy, NCT01265433, accessed January 03, 2011 http://www.clinicaltrials.gov
11. Anonymous. (n.d. i). Short Neoadjuvant Hemithoracic IMRT for MPM, NCT00797719. Available at: http://www.clinicaltrials.gov/ct2/show/ [accessed January 03, 2011].
12. Anonymous. (n.d. j). Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for StandardTreatment, NCT00585845. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
13. Anonymous. (n.d. k). Tomotherapy Treatment for Mesothelioma, NCT00469196. Available at: http://www.clinicaltrials.gov/ct2/show/ [accessed January 03, 2011].
14. © in Patients with Unresectable, Refractory, Malignant Mesothelioma NCT00551252. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
15. Anonymous. (2009b). A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed As First Line Treatment in Patients with Malignant Pleural Mesothelioma, Mesomab Nct00996567. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
16. Anonymous. (2009c). A Study to Find the Best Dose of SU011248 When Given with Pemetrexed, Pemetrexed and Cisplatin or Pemetrexed and Carboplatin in Patients with Advanced Solid Tumours NCT00528619. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
17. Anonymous. (2009d). A Study of MORAb-009 in Subjects with Pancreatic Cancer, Mesothelioma or Certain Types of Ovarian or Lung Cancer NCT00325494. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
18. Anonymous. (2009e). Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma NCT00137826. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
19. Anonymous. (2009f). Bortezomib and Cisplatin as First-Line Therapy in Treating Patients with Malignant Mesothelima NCT00458913. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
20. Anonymous. (2009g). Bortezomib in Treating Patients with Malignant Pleural Mesothelioma NCT00325494. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
21. Anonymous. (2009h). Cisplatin, Pemetrexed and Imatinib Mesylate in Malignant Mesothelioma NCT00402766. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
22. Anonymous. (2009i). PXD101 as Second-Line Therapy in Treating Patients with Malignant Mesothelioma of the Chest that Cannot be Removed by Surgery NCT00365053. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
23. Anonymous. (2009j). Sorafenib in Treating Patients with Malignant Mesothelioma NCT00107432. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
24. Anonymous. (2009k). Study Using Chemotherapy Followed By Intensity Modulated Radiation Therapy To The Pleura In Patients With Locally Advanced But Unresectable Malignant pleural Mesothelioma NCT00715611. Available at: http://www.clinicaltrials.gov/ct2/show/ [accessed on November 3, 2009].
25. Anonymous. (2009l). Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma NCT00128102. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
26. Anonymous. (2009m). Sunitinib in Treating Patients with Advanced Malignant Pleural Mesothelioma NCT00392444. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
27. Anonymous. (2010). Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma 12293. Available at: http://www.clinicaltrials.gov [accessed January 03, 2011].
28. Baas, P., Boogerd, W., Dalesio, O., Haringhuizen, A., Custers, F., and van Zandwijk, N. (2005). Thalidomide in patients with malignant pleural mesotheliom. Lung Cancer 48, 291-296.
29. Baas, P., Buikhuisen, W., Dalesio, O., Vincent, A., Pavlakis, N., Van Klaveren, R., Schramel, F., Custers, F., Schouwink, H., Burgers, S. A., Netherlands Cancer Institute, Amsterdam, Netherlands, The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands, Royal North Shore Hospital, Sydney University, Sydney, Australia, Erasmus University Medical Center, Rotterdam, Netherlands; St Antonius Hospital, Nieuwegein, Netherlands; Atrium Hospital, Heerlen, Netherlands, Medisch Spectrum Twente, Enschede, Netherlands, and The Netherlands Cancer Institute, Amsterdam, Netherlands. (2011). A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J. Clin. Oncol. 29(Suppl.). [abstract 7006]
30. Baldini, E. H., Recht, A., Strauss, G. M., DeCamp, MM. Jr., Swanson, S. J., Liptay, M. J., Mentzer, S. J., and Sugarbaker, D. J. (1997). Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 63, 334-338.
31. Banchereau, J., and Palucka, A. K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306.
32. Berghmans, T., Lafitte, J.-J., Mascaux, C., Meert, A.-P., Paesmans, M., and Sculier, J.-P. (2003). Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 41, 245-256.
33. Bertino, P., Porta, C., Barbone, D., Germano, S., Busacca, S., Pinato, S., Tassi, G., Favoni, R., Gaudino, G., and Mutti, L. (2007). Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 62, 690-695.
34. Branchaud, R. M., MacDonald, J. L., and Kane, A. B. (1989). Induction of angiogenesis by intraperitoneal injection of asbestos fibers. FASEB J. 3, 1747-1752.
35. Brockstedt, G., Giedlin, M. A., Leong, M. L., Bahjat, K. S., Gao, Y., Luckett, W., Liu, W., Cook, D. N., Portnoy, D. A., and Dubensky, T. W. Jr. (2004). Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. U.S.A. 101, 13832-13837.
36. Ceresoli, G., Castagneto, B., Zucali, P. A., Favaretto, A., Mencoboni, M., Grossi, F., Cortinovis, D., Del Conte, G., Ceribelli, A., Bearz, A., Salamina, S., De Vincenzo, F., Cappuzzo, F., Marangolo, M., Torri, V., and Santoro, A. (2008). Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br. J. Cancer 99, 51-56.
37. Chang, K., Pai, L. H., Pass, H., Pogrebniak, H. W., Tsao, M. S., Pastan, I., and Willingham, M. C. (1992). Monoclonal antibody K1 reacts with epithelial mesothelioma but not lung adenocarcinoma. Am. J. Surg. Pathol. 16, 259-268.
38. Chapman, E., Berenstein, G., García Diéguez, M., and Ortiz, Z. (2006). Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst. Rev. 3:CD003880.
39. Chowdhury, S., and Pastan, I. (1999). Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17, 568-572.
40. Chowdhury, S., Viner, J. L., Beers, R., and Pastan, I. (1998). Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. U. S. A 25, 669-674.
41. Cortese, J. F., Gowda, A. L., Wali, A., Eliason, J. F., Pass, H. I., and Everson, R. B. (2006). Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int. J. Cancer 118, 521-522.
42. Cranmer, L. D., Trevor, K. T., and Hersh, E. M. (2004). Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother. 53, 275-306.
43. Dazzi, H., Hasleton, P. S., Thatcher, N., Wilkes, S., Swindell, R., and Chatterjee, A. K. (1990). Malignant pleural mesothelioma and epidermal growth factor receptor, relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer 61, 924-926.
44. De Perrot, M., Feld, R., Cho, B. C., Bezjak, A., Anraku, M., Burkes, R., Roberts, H., Tsao, M. S., Leighl, N., Keshavjee, S., and Johnston, M. R. (2009). Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27, 1413-1418.
45. Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J. M., Nusgens, B. V., and Castronovo, V. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signalling. Oncogene 21, 427-436.
46. Edwards, J. G., Cox, G., Andi, A., Jones, J. L., Walker, R. A., Waller, D. A., and O'Byrne, K. J. (2001). Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br. J. Cancer 85, 863-868.
47. Ellis, P., Davies, A., Evans, K., Haynes, A. E., Lloyd, N. S., and Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. (2006). The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J. Thorac. Oncol. 1, 591-601.
48. Fennell, D. A., Chacko, A., and Mutti, L. (2008). BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27, 1189-1197.
49. Fennell, D. A., Steele, J. P., Shamash, J., Evans, M. T., Wells, P., Sheaff, M. T., Rudd, R. M., and Stebbing, J. (2007). Efficacy and safety of first-or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 109, 93-99.
50. Flores, R. M., Krug, L. M., Rosenzweig, K. E., Venkatraman, E., Vincent, A., Heelan, R., Akhurst, T., and Rusch, V. W. (2006). Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J. Thorac. Oncol. 1, 289-295.
51. Flores, R. M., Pass, H. I., Seshan, V. E., Dycoco, J., Zakowski, M., Carbone, M., Bains, M. S., and Rusch, V. W. (2008). Extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) in the surgical management of malignant pleural mesothelioma (MPM): results in 663 patients. J. Thorac. Cardiovasc. Surg. 135, 620-626.
52. Garland, L. L., Rankin, C., Gandara, D. R., Rivkin, S. E., Scott, K. M., Nagle, R. B., Klein-Szanto, A. J., Testa, J. R., Altomare, D. A., and Borden, E. C. (2007). Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol. 25, 2406-2413.
53. Giaccone, G., O'Brien, M. E., Byrne, M. J., Bard, M., Kaukel, E., and Smit, B. (2002a). Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur. J. Cancer 38(Suppl. 8), S19-S24.
54. Giaccone, G., O'Brien, M., Byrne, M., Barde, M., Kaukelf, E., and Smit, B. (2002b). Current phase II data for ZD0473 in patients with mesothelioma who had relapsed following one prior chemotherapy regimen. Eur. J. Cancer 38(Suppl. 8), S19-S24.
55. Giedlin, M. A., Bahjat, K. S., Prell, R. A., et al. (2007). "Activation and expansion of hepatic NK cells promotes innate antitumor immunity and long-lived CD8+ T cell memory following treatment with attenuated Listeria monocytogenes," in AACR Proceedings [Abstract #1877, April 14]
56. Gish, R. G., Porta, C., Lazar, L., Ruff, P., Feld, R., Croitoru, A., Feun, L., Jeziorski, K., Leighton, J., Gallo, J., and Kennealey, G. T. (2007). Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 25, 3069-3075.
57. Glinsky, G. V., Berezovska, O., and Glinskii, A. B. (2005). Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115, 1503-1521.
58. Gordon, G. J., Jensen, R. V., Hsiao, L. L., Gullans, S. R., Blumenstock, J. E., Richards, W. G., Jaklitsch, M. T., Sugarbaker, D. J., and Bueno, R. (2003). Using gene expression ratios to predict outcome among patients with mesothelioma. J. Natl. Cancer Inst. 95, 598-605.
59. Gordon, G. J., Mani, M., Maulik, G., Mukhopadhyay, L., Yeap, B. Y., Kindler, H. L., Salgia, R., Sugarbaker, D. J., and Bueno, R. (2007). Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 10, 1007.
60. Gordon, G. J., Rockwell, G. N., Godfrey, P. A., Jensen, R. V., Glickman, J. N., Yeap, B. Y., Richards, W. G., Sugarbaker, D. J., and Bueno, R. (2005a). Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin. Cancer Res. 11, 4406-4414.
61. Gordon, G. J., Rockwell, G. N., Jensen, R. V., Rheinwald, J. G., Glickman, J. N., Aronson, J. P., Pottorf, B. J., Nitz, M. D., Richards, W. G., Sugarbaker, D. J., and Bueno, R. (2005b). Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am. J. Pathol. 166, 1827-1840.
62. UICC. (2006). Prognostic Factors in Cancer, 3rd Edn. eds M. K. Gospodarowicz, B. O'Sullivan, and L. H. Sobin. (Frankfurt: Wiley-Liss), 165-168. [ISBN-13978-0-470-03801-7].
63. Govindan, R., Kratzke, R. A., Herndon, J. E. II, Niehans, G. A., Vollmer, R., Watson, D., Green, M. R., Kindler, H. L., and Cancer Leukemia Group B (CALGB 30101). (2005). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 11, 2300-2304.
64. Halstead, J. C., Lim, E., Venkateswaran, R. M., Charman, S. C., Goddard, M., and Ritchie, A. J. (2005). Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur. J. Surg. Oncol. 31, 314-320.
65. Harvey, V. J., Slevin, M. L., Ponder, B. A., Blackshaw, A. J., and Wrigley, P. F. (1984). Chemotherapy of diffuse malignant mesothelioma, phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 54, 961-964.
66. Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., and Pastan, I. (2007). Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesotheline expressing mesothelioma, ovarian and pancreatic cancers. Clin. Cancer Res. 13, 5144-5149.
67. Hegmans, J. P., Hemmes, A., Aerts, J. G., Hoogsteden, H. C., and Lambrecht, B. N. (2005). Immunotherapy of murine malignant mesothelioma using tumour lysate-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 171, 1168-1177.
68. Hegmans, J. P., Hemmes, A., Hammad, H., Boon, L., Hoogsteden, H. C., and Lambrecht, B. N. (2006). Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J. 27, 1086-1095.
69. Hillerdal, G., Sorensen, J. B., Sundström, S., Riska, H., Vikström, A., and Hjerpe, A. (2008). Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J. Thorac. Oncol. 3, 1325-1331.
70. Ho, M., Hassan, R., Zhang, J., Wang, Q. C., Onda, M., Bera, T., and Pastan, I. (2005). Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin. Cancer Res. 11, 3814-3820.
71. Hoang, C. D., D'Cunha, J., Kratzke, M. G., Casmey, C. E., Frizelle, S. P., Maddaus, M. A., and Kratzke, R. A. (2004). Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125, 1843-1852.
72. Hughes, A. N., Rafi, I., Griffin, M. J., Calvert, A. H., Newell, D. R., Calvete, J. A., Johnston, A., Clendeninn, N., and Boddy, A. V. (1999). Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clin. Cancer Res. 5, 111-118.
73. Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., Lillemoe, K. D., O'Reilly, S., Abrams, R. A., Pardoll, D. M., Cameron, J. L., and Yeo, C. J. (2001). Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156.
74. Jahan, T. M., Gu, L., Wang, X., Kratzke, R. A., Dudek, A. Z., Green, M. R., Vokes, E. E., and Kindler, H. L. (2006). Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J. Clin. Oncol. (Suppl. 18), 24 [abstract no. 7081].
75. Janne, P., Wang, X., Krug, L., Hodgson, L., Vokes, E. E., and Kindler, H. L. (2007). Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J. Clin. Oncol. 25 [abstract no. 7707].
76. Jassem, J., Ramlau, R., Santoro, A., Schuette, W., Chemaissani, A., Hong, S., Blatter, J., Adachi, S., Hanauske, A., and Manegold, C. (2008). Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J. Clin. Oncol. 26, 1698-1704.
77. Jotte, R., Conkling, P., Reynolds, C., Galsky, M. D., Klein, L., Fitzgibbons, J. F., McNally, R., Renschler, M. F., and Oliver, J. W. (2010). Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J. Clin. Oncol. 6. [Epub ahead of print].
78. Karrison, T., Kindler, H., Gandara, D., Lu, C., Guterz, T. L., Nichols, K., Chen, H., Stadler, W. M., and Vokes, E. E. (2007). Final analysis of a multi-centre, double-lind, placebo-controlled, randomised phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J. Clin. Oncol. 25. [abstract no. 7526].
79. Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584.
80. Kettunen, E., Vivo, C., Gattacceca, F., Knuutila, S., and Jaurand, M. C. (2004). Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment. Cancer Genet. Cytogenet. 152, 42-51.
81. Kindler, H. L., Burris, H. A. III, Sandler, A. B., and Oliff, I. A. (2009). A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest. New Drugs 27, 75-81.
82. Klabatsa, A., Sheaff, M. T., Steele, J. P., Evans, M. T., Rudd, R. M., and Fennell, D. A. (2006). Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer 51, 53-59.
83. Krug, L. M., Curley, T., Schwartz, L., Richardson, S., Marks, P., Chiao, J., and Kelly, W. K. (2006). Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin. Lung Cancer 7, 257-261.
84. Krug, L. M., Heelan, R. T., Kris, M. G., Venkatraman, E., and Sirotnak, F. M. (2007). Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J. Thorac. Oncol. 2, 317-320.
85. Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., Flores, R., Friedberg, J. S., Pisters, K., Monberg, M., Obasaju, C. K., and Vogelzang, N. J. (2009). Multicentre phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27, 3007-3013.
86. Kumar-Singh, S., Weyler, J., Martin, M. J., Vermeulen, P. B., and Van Marck, E. (1999). Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J. Pathol. 189, 72-78.
87. Lee, T. C., Zhang, Y., Aston, C., Hintz, R., Jagirdar, J., Perle, M. A., Burt, M., and Rom, W. N. (1993). Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res. 53, 2858-2864.
88. Lopez-Rios, F., Chuai, S., Flores, R., Shimizu, S., Ohno, T., Wakahara, K., Illei, P. B., Hussain, S., Krug, L., Zakowski, M. F., Rusch, V., Olshen, A. B., and Ladanyi, M. (2006). Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 66, 2970-2979.
89. Maasilta, P. (1991). Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 20, 433-438.
90. Marks, P. A., Richon, V. M., Breslow, R., and Rifkind, R. A. (2001). Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13, 477-483.
91. Martin-Ucar, A. E., Edwards, J. G., Rengajaran, A., Muller, S., and Waller, D. A. (2001). Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur. J. Cardiothorac. Surg. 20, 1117-1121.
92. Mathy, A., Baas, P., Dalesio, O., and van Zandwijk, N. (2005). Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50, 83-86.
93. May, R. J., Dao, C., Pinilla-Ibarz, J., Korontsvit, T., Zakhaleva, V., Zhang, R. H., Maslak, P., and Scheinberg, D. A. (2007). Peptide epitopes from the Wilms' tumour 1 oncoprotein stimulate CD4+ and CD8+ T-cells that recognize and kill human malignant mesothelioma tumour cells. Clin. Cancer Res. 13, 4547-4555.
94. Millward, W., Parnis, F., Byrne, M., Powell, A., Dunleavey, R., Lynch, K., and Boyer, M. J. (2003). Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 22. [abstract no. 912].
95. Mohr, S., Bottin, M. C., Lannes, B., Neuville, A., Bellocq, J. P., Keith, G., and Rihn, B. H. (2004). Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 86, 13-19.
96. Muirhead, R., and O'Rourke, N. (2007). Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource. Eur. Res. J. 30, 1021.
97. Nakas, A., Martin-Ucar, A. E., Edwards, J. G., and Waller, D. A. (2008). The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 33, 83-88.
98. Nowak, A. K., Millward, M. J., Francis, R., van der Schaaf, A., Musk, A. W., and Byrne, M. J. (2008). Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J. Clin. Oncol. 26(Suppl.), :439s. [abstract 8063].
99. Ohta, Y., Shridhar, V., Bright, R. K., Kalemkerian, G. P., Du, W., Carbone, M., Watanabe, Y., and Pass, H. I. (1999). VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 1, 54-61.
100. Opitz, I., Kestenholz, P., Lardinois, D., Müller, M., Rousson, V., Schneiter, D., Stahel, R., and Weder, W. (2006). Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 29, 579-584.
101. Ordanez, N. G. (2007). What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma: a review and update. Hum. Pathol. 38, 1-6.
102. Ordonez, N. G. (2003). Value of mesothelin immunostaining in the diagnosis of mesothelioma, Mod. Pathol. 16, 192-197.
103. Pass, H. I., Liu, Z., Wali, A., Bueno, R., Land, S., Lott, D., Siddiq, F., Lonardo, F., Carbone, M., and Draghici, S. (2004). Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res. 10, 849-859.
104. Pavlakis, N., Abraham, R., and Harvie, R. (2003). Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomised phase II studies. Lung Cancer 41(Suppl. 2), :S11. [abstract].
105. Porta, C., Mutti, L., and Tassi, G. (2007). Negative results of an Italian group for mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 59, 149-150.
106. Porta, C., Zimatore, M., Bonomi, L., Imarisio, I., Paglino, C., Sartore-Bianchi, A., and Mutti, L. (2005). Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48, 429-434.
107. Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., and Armand, J. P. (2004). Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22, 2336-2347.
108. Rice, D. C., Stevens, C. W., Correa, A. M., Vaporciyan, A. A., Tsao, A., Forster, K. M., Walsh, G. L., Swisher, S. G., Hofstetter, W. L., Mehran, R. J., Roth, J. A., Liao, Z., and Smythe, W. R. (2007). Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 84, 1685-1692.
109. Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., Brendel, E., Schwartz, B., Ludwig, M., Flashar, C., Voigtmann, R., Scheulen, M. E., Seeber, S., and Strumberg, D. (2006). Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumours. Ann. Oncol. 17, 866-873.
110. Righi, L., Papotti, M. G., Ceppi, P., Billè, A., Bacillo, E., Molinaro, L., Ruffini, E., Scagliotti, G. V., and Selvaggi, G. (2010). Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J. Clin. Oncol. 28, 1534-1539.
111. Rosenzweig, K., Krug, L., Laser, B., Yorke, E., Flores, R., Brown, A., and Rusch, V. W. (2009). Feasibility of pleural intensity-modulated radiation therapy (IMRT) for malignant mesothelioma. J. Thorac. Oncol. 4, S774.
112. Rusch, V. (2009). The MARS trial: resolution of the surgical controversies in mesothelioma? J. Thorac. Oncol. 4, 1189-1191.
113. Rusch, V. W., Rosenzweig, K., Venkatraman, E., Leon, L., Raben, A., Harrison, L., Bains, M. S., Downey, R. J., and Ginsberg, R. J. (2001). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 122, 788-795.
114. Santoro, A., O'Brien, M. E., Stahel, R. A., Nackaerts, K., Baas, P., Karthaus, M., Eberhardt, W., Paz-Ares, L., Sundstrom, S., Liu, Y., Ripoche, V., Blatter, J., Visseren-Grul, C. M., and Manegold, C. (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J. Thorac. Oncol. 3, 756-763.
115. Sartore-Bianchi, A., Gasparri, F., Galvani, A., Nici, L., Darnowski, J. W., Barbone, D., Fennell, D. A., Gaudino, G., Porta, C., and Mutti, L. (2007). Bortezomib inhibits nuclear factor-kappa B-dependent survival and has potent in vivo activity in mesothelioma. Clin. Cancer Res. 13, 5942-5951.
116. Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., Hennequin, C., Hillerdal, G., Le Péchoux, C., Mutti, L., Pairon, J.-C., Stahel, R., van Houtte, P., van Meerbeeck, J., Waller, D., and Weder, W. (2010). Guidelines of the ERS/ESTS for management of malignant pleural mesothelioma. Eur. Res. J. 35, 479-495.
117. Senan, S. (2003). Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr. Opin. Oncol. 15, 144-147.
118. Sørensen, J. B., Frank, H., and Sørensen, P. (2007). Phase II study of carboplatin and vinorelbine (i.v. and orally) first line chemotherapy in non-resectable malignant pleural mesothelioma (MPM). J. Thorac. Oncol. 2, S610-S611.
119. Sorensen, J. B., Sundstrom, S., Perell, K., and Thielsen, A. K. (2007). Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J. Thorac. Oncol. 2, 147-152.
120. Sorensen, P. G., Bach, F., Bork, B., and Hansen, H. H. (1985). Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat. Rep. 69, 1431-1432.
121. Soysal, O., Karaoglanoglu, N., Demiracan, S., Topçu, S., Tastepe, I., Kaya, S., Unlü, M., and Cetin, G. (1997). Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur. J. Cardiothorac. Surg. 11, 210-213.
122. Stahel, R. A., Weder, W., Felip, E., and ESMO Guidelines Working Group. (2009). Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 73-75.
123. Steinman, R. M., and Dhodapkar, M. (2001). Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94, 459-473.
124. Sterman, D. H., Recio, A., Carroll, R. G., Gillespie, C. T., Haas, A., Vachani, A., Kapoor, V., Sun, J., Hodinka, R., Brown, J. L., Corbley, M. J., Parr, M., Ho, M., Pastan, I., Machuzak, M., Benedict, W., Zhang, X. Q., Lord, E. M., Litzky, L. A., Heitjan, D. F., June, C. H., Kaiser, L. R., Vonderheide, R. H., Albelda, S. M., and Kanther, M. (2007). A phase i clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin. Cancer Res. 13, 4456.
125. Sterman, D. H., Recio, A., Vachani, A., Sun, J., Cheung, L., DeLong, P., Amin, K. M., Litzky, L. A., Wilson, J. M., Kaiser, L. R., and Albelda, S. M. (2005). Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin. Cancer Res. 11, 7444.
126. Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M., and Kaiser, L. R. (1998). Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: results of a phase 1 clinical trial in malignant mesothelioma. Hum. Gene Ther. 9, 1083-1092.
127. Strizzi, L., Catalano, A., Vianale, G., Orecchia, S., Casalini, A., Tassi, G., Puntoni, R., Mutti, L., and Procopio, A. (2001). Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 193, 468-475.
128. Sugarbaker, D. J. (2006). Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J. Thorac. Oncol. 1, 175-176.
129. Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., DeCamp MM, J. r., Swanson, S. J., Bueno, R., Lukanich, J. M., Baldini, E. H., and Mentzer, S. J. (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy for malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117, 54-63.
130. Sugarbaker, D. J., Jaklitsch, M. T., Bueno, E., Richards, W., Lukanich, J., Mentzer, S. J., Colson, Y., Linden, P., Chang, M., Capalbo, L., Oldread, E., Neragi-Miandoab, S., Swanson, S. J., and Zellos, L. S. (2004). Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J. Thorac. Cardiovasc. Surg. 128, 138-146.
131. (2009). Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma With Or Without Hemithoracic Radiotherapy. A Randomised Multicentre Phase II Trial (SAKK 1704). Available at: http://sakk.ch/en/download/105 [accessed on Janaury 03, 2011].
132. Talbot, D. C., Margery, J., Dabouis, G., Dark, G., Taylor, H., Boussemart, H., Cadic, V., Pinel, M. C., Rivière, A., Ollivier, L., and Ruffié, P. (2007). Phase II study of vinflunine in malignant pleural mesothelioma. J. Clin. Oncol. 25, 4751-4756.
133. Teh, E., Fiorentino, F., Tan, C., and Treasure, T. (2010). A systematic review of lungsparing extirpative surgery for pleural mesothelioma. J. R. Soc. Med. 104, 69-80.
134. Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y. C., Huang, L. Q., Laheru, D. A., Goggins, M., Hruban, R. H., and Jaffee, E. M. (2004). Mesothelin-specific CD8(+) T cell response provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 20, 297-306.
135. Treasure, T., Bliss, J., Tan, C., Entwisle, J., Waller, D., O'Brien, M., Coombes, G., Webster-Smith, M., Kilburn, L., Snee, M., Thomas, G., Darlison, L., Lang-Lazdunski, L., and Peto, J. (2010). Principal Results of the Feasibility Phase of the Mesothelioma and Radical Surgery Trial (MARS-feasibility). Available at: http://www.ncri.org.uk/ncriconference/2010abstracts/abstracts/LB74.htm
136. Treasure, T., Waller, D., Swift, S., and Peto, J. (2004). Radical surgery for mesothelioma, the epidemic is still to peak and we need more research to manage it. BMJ 328, 237-238. doi: 10.1136/bmj.328.7434.237
137. Treasure, T., Waller, D., Tan, C., Entwisle, J., O'Brien, M., O'Byrne, K., Thomas, G., Snee, M., Spicer, J., Landau, D., Lang-Lazdunski, L., Bliss, J., Peckitt, C., Rogers, S., Marriage Née Denholm, E., Coombes, G., Webster-Smith, M., Peto, J., Guy's and St Thomas' Hospital, London, UK. tom.treasure@gmail.com. (2009). The mesothelioma and radical surgery randomised controlled trial: the MARS feasibility study. J. Thorac. Oncol. 4, 1254-1258.
138. Ung, Y. C., Yu, E., Falkson, C., Haynes, A. E., Stys-Norman, D., Evans, W. K., and Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. (2006). The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother. Oncol. 80, 13-18.
139. Van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., Giaccone, G., European Organisation for Research Treatment of Cancer Lung Cancer Group and National Cancer Institute of Canada. (2005). Randomised phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23, 6881-6889.
140. Van Schil, P., Baas, P., Gaafar, R., Maat, A. P., Van de Pol, M., Hasan, B., Klomp, H. M., Abdelrahman, A. M., Welch, J., van Meerbeeck, J. P., and European Organisation for Research Treatment of Cancer Lung Cancer Group. (2010). Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur. Res. J. 36, 1362-1369.
141. Villano, J., Husain, A. J., Stadler, W. M., Hanson, L. L., Vogelzang, N. J., Kindler, H. L., and University of Chicago, Chicago, IL. (2004). A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). Proc. Am. Soc. Clin. Oncol. 663. [abstract no. 7200].
142. Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., Niyikiza, C., and Paoletti, P. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636-2644.
143. Waller, D. A., Morritt, G. N., and Forty, J. (1995). Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 5, 1454-1456.
144. Wang, Y., Zhao, R., Chattopadhyay, S., and Goldman, I. D. (2002). A novel folate transport activity in human mesothelioma cell lines with high-affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res. 62, 6434-6437. [Erratum in: Cancer Res. 2003 Oct 15; 63(20):7004].
145. Watanabe, Y., Kojima, T., Kagawa, S., Uno, F., Hashimoto, Y., Kyo, S., Mizuguchi, H., Tanaka, N., Kawamura, H., Ichimaru, D., Urata, Y., and Fujiwara, T. (2010). A novel translational approach for human malignant pleural mesohtelioma: heparanase-assisted dual virotherapy. Oncogene 29, 1145-1154.
146. Webber, S., Bartlett, C. A., Boritzki, T. J., Hillard, J. A., Howland, E. F., Johnston, A. L., Kosa, M., Margosiak, S. A., Morse, C. A., and Shetty, B. V. (1996). AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol. 37, 509-517.
147. Weder, W., Kestenholz, P., Taverna, C., Bodis, S., Lardinois, D., Jerman, M., and Stahel, R. A. (2004). Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 22, 3451-3457.
148. Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., Lardinois, D., Betticher, D., Schmid, R., Stupp, R., Ris, H. B., Jermann, M., Mingrone, W., Roth, A. D., Spiliopoulos, A., and Swiss Group for Clinical Cancer Research. (2007). Multicentre trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 18, 1196-1202.
149. Yokokawa, J., Palena, C., Arlen, P., Hassan, R., Ho, M., Pastan, I., Schlom, J., and Tsang, K. Y. (2005). Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin. Cancer Res. 11, 6342-6351.
150. Zalcman, G., Margery, G., Scherpereel, A., Astoul, P., Monnet, I., Milleron, B. J., Paule, L. M., André, M., Moro-Sibilot, D., and Mazieres, J. on behalf of IFCT; CHU Côte de Nacre, Caen, France, HIA Percy, Clamart, France, CHRU Albert Calmette, Lille, France, University Hospital Sainte-Marguerite, Marseille, France, CHI, Creteil, France, Tenon University Hospital, Paris, France, IFCT, Paris, France, University Hospital Morvan and HIA, Brest, France, Hôpital Universitaire, Grenoble, France, and University Hospital Larrey, Toulouse, France. (2010). IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J. Clin. Oncol. 28, Abstract 7020. [ASCO Annual Meeting Proceedings].
151. Zhang, Y., Xiang, L., Hassan, R., Paik, C. H., Carrasquillo, J. A., Jang, B. S., Le, N., Ho, M., and Pastan, I. (2006). Synergistic antitumour activity of taxol and immunotoxin SS1P in tumour-bearing mice. Clin. Cancer Res. 12, 4695-4701.
152. Zucali, P. A., Ceresoli, G. L., Garassino, I., De Vincenzo, F., Cavina, R., Campagnoli, E., Cappuzzo, F., Salamina, S., Soto Parra, H. J., and Santoro, A. (2008). Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112, 1555-1561.